In addition, drug development targeting specific ubiquitin E3 ligases has attracted much attention, such as the small molecule inhibitor Nutlin targeting MDM2, which can block the degradation of p53 and enhance its anti-tumor activity [18, 19]. The gene discussed is TP53; the disease is neoplasm.